UK markets closed

HUM Jan 2025 310.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
5.320.00 (0.00%)
As of 01:48PM EDT. Market open.
Full screen
Previous close5.32
Open5.15
Bid6.00
Ask6.70
Strike310.00
Expiry date2025-01-17
Day's range5.15 - 5.40
Contract rangeN/A
Volume11
Open interest1.63k
  • Business Wire

    Humana Accelerates Commitment to Helping Seniors Choose Right Health Plan, Announces Minority Investment in Healthpilot

    LOUISVILLE, Ky., July 17, 2024--Leading health and well-being company Humana Inc. (NYSE: HUM), through its payor-agnostic insurance brokerage business, today announced a minority investment in Healthpilot, a company pioneering the development of a personalized and simpler digital enrollment experience for seniors exploring their Medicare options. The financial investment by Humana supports both companies’ visions to create a more efficient, transparent, and consumer-centric healthcare ecosystem.

  • Business Wire

    Humana Named "2024 Best Places to Work for People with Disabilities"

    LOUISVILLE, Ky., July 16, 2024--Humana Inc. (NYSE: HUM) scored 100 on the Disability Equality Index® for the fifth consecutive year, demonstrating the company’s continued commitment to building and maintaining a culture of belonging where all employees of all abilities can feel valued and have both opportunity and support to reach their full potential.

  • Yahoo Finance Video

    FTC plans to sue top 3 PBMs over insulin prices: WSJ

    The Federal Trade Commission (FTC) is looking to take legal action against the three largest pharmacy benefit managers (PBMs) in the United States: CVS Health (CVS), UnitedHealth Group (UNH), and Cigna (CI), according to a report from The Wall Street Journal. The potential lawsuit stems from concerns over escalating drug prices and alleged anticompetitive practices, particularly for medications like insulin. Yahoo Finance health reporter Anjalee Khemlani breaks down the details, exploring the implications for the healthcare industry, consumers, and the broader pharmaceutical market. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Angel Smith